Stellate Ganglion Block to Prevent Atrial Fibrillation in Cardiac Surgery Patients

Overview

Información sobre este estudio

The purpose of this study is to evaluate stellate ganglion blockade with local anesthetic intraoperatively to reduce the development of postoperative atrial fibrillation.

Atrial fibrillation is an important postoperative complication following cardiac surgery despite many attempts to reduce the incidence. Temporary stellate ganglion blockade reduces ventricular arrythmias in various circumstances with animal and early human data also showing an effect on the development of atrial fibrillation. The duration of arrythmia control outlasts the expected duration of local anesthetic effect by a significant duration.  Stellate ganglion blockade has potential for great impact reducing the burden of POAF including large cost savings, reduction in hospital length of stay, and improvement in quality of life via reduction of large degree of morbidity. If effective, this could revolutionize cardiac surgery care.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Patient presenting for cardiac surgery at the Mayo Clinic in Rochester, Minnesota.

- Patients scheduled to undergo mitral or aortic valve surgery with or without coronary
artery bypass grafting.

Exclusion Criteria:

- Patients with a history of permanent atrial fibrillation, left or right ventricular
assist device implantation or explantation.

- Patients with procedures not requiring cardiopulmonary bypass.

- Patients with procedures requiring deep hypothermic circulatory arrest.

- Patients with active infection or sepsis.

- Pre-operative immunosuppressive medication use (including steroid use).

- Pre-operative anti-arrhythmic medication use (aside from beta-blockers).

- Patients with Immunodeficiency syndrome.

- Patients with known neurologic disorder.

- Patients requiring left internal jugular central line placement.

- Performance of Maze procedures or left atrial appendage ligation procedures will not
exclude patients from potential enrollment as atrial fibrillation still occurs
postoperatively while the scarring from the Maze procedure forms.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 7/27/22. Questions regarding updates should be directed to the study team contact

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Erica Wittwer, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Erica Wittwer M.D., Ph.D.

(507) 255-6276

Wittwer.Erica@mayo.edu

More information

Publicaciones

Publications are currently not available